The Zydus Group has forayed into the generics market of Japan and set up a wholly-owned subsidiary in the country.The subsidiary, Zydus Pharma, would market formulation generics and active pharmaceutical ingredients (APIs) in Japan, according to an official release issued by company to the BSE today.Zydus Pharma would initiate the process for registration of products in 2007, besides marketing generics.The company would also explore collaborations and alliances with Japanese pharmaceutical companies in areas such as joint research and development, co-marketing, contract manufacturing for APIs, intermediates and formulations, it said.The subsidiary, headquartered at Shinjuku-ku in Tokyo, would be headed by Kazuhiro Kawabata as president."Meeting healthcare needs with affordable, high quality therapies has been our constant endeavour. We have been engaged in building healthier communities globally and reaching out to people in the US, Europe, Latin America and across the world. We now have an opportunity to extend our commitment to the people of Japan. We hope to do this by leveraging our strengths and expertise as a global healthcare provider and providing innovative healthcare solutions", Pankaj R Patel, CMD of the Zydus Group, said.
